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ABSTRACT
Objectives: There are few published studies on the
epidemiology of Langerhans cell histiocytosis (LCH). We
undertook a survey to ascertain all newly diagnosed cases
aged 0–16 years in the UK and Republic of Ireland.
Design: Three methods of ascertainment were used: the
British Paediatric Surveillance Unit (BPSU) system, a
survey by Newcastle University, and the Children’s Cancer
and Leukaemia Group (CCLG) registry. Deaths data were
obtained from the UK Office for National Statistics and the
Central Statistics Office in Ireland. Clinicians who reported
cases were sent a questionnaire to obtain demographic
and clinical details.
Results: Over the 2-year period, 94 cases were
identified. The age-standardised incidence rate of LCH in
children aged 0–14 years was 4.1 per million per year.
The sex ratio (M:F) was 1.5:1 and the median age at
diagnosis was 5.9 years. Single system disease (pre-
dominantly bony involvement) accounted for 73% of cases
and 27% had multisystem disease of whom 7% had
involvement of ‘‘risk organs’’ (liver, lung, spleen and bone
marrow). Three children died, two of whom were
diagnosed after death.
Conclusions: This is the first study of LCH to use an
active surveillance method with additional sources of
ascertainment. Our incidence is comparable with those in
other national reports, although it is likely to be an
underestimate as each method may have missed some
cases, either diagnosed or undiagnosed.
Langerhans cell histiocytosis (LCH) is a disorder of
regulation of antigen-presenting dendritic cells of
the immune system resulting in a spectrum of
single system or multisystem organ dysfunction.
Skin involvement typically presents as ‘‘resistant’’
eczema, while affected bones develop granulomata
which may resolve spontaneously or result in long-
term deformity. On the other hand, isolated
lymphadenopathy or diabetes insipidus may be
the only manifestation of the disease. Multisystem
disease involving any of the so-called risk organs,
including bone marrow, lungs, liver and spleen,
may be associated with a poor prognosis.
The aetiology of LCH is unknown and its
epidemiology remains poorly documented.
Reliable data on incidence are difficult to gather,
but there have been a few international and
regional studies of the disease and reports from
cancer registries with geographically defined popu-
lations.1–9 However, none has used a prospective
method of case ascertainment such as that used by
the British Paediatric Surveillance Unit (BPSU) of
the Royal College of Paediatrics and Child Health
(RCPCH).10
A 2-year national survey of children newly
diagnosed with LCH and resident in the UK or
Republic of Ireland (RoI) began in June 2003. The
aims were to ascertain all cases using multiple,
complementary sources and to describe the inci-
dence of LCH by age, sex, ethnic origin, season and
region. Secondary aims were to identify any
potentially relevant maternal history or associated
illnesses, to describe presenting features, referral
patterns, treatment, and outcome after 1 and
2 years, and to assess mortality.
METHODS
Cases were ascertained between June 2003 and
May 2005 using three methods. The first was via
the BPSU which undertakes active surveillance of
uncommon childhood conditions using a network
of over 2600 multispecialty paediatricians in the
UK and RoI. Participants are sent a monthly case
report card containing a ‘‘menu’’ of conditions
under surveillance and are asked to report any new
cases or ‘‘none seen’’. The overall response rate is
over 90%.10 Positive returns are notified to the
study team who then collect further information
from clinicians.
Since cases may be seen by clinicians who are
not paediatricians, two additional sources of
ascertainment were used. A national mailing
exercise to non-RCPCH clinicians was carried out
in parallel with the BPSU survey by the authors
from Newcastle University at 6-monthly intervals.
What is already known on this topic
Langerhans cell histiocytosis can occur in children
of any age with a peak in diagnosis between 1 and
3 years of age.
What this study adds
c The incidence of Langerhans cell histiocytosis
(LCH) in children in the UK and Republic of
Ireland aged 0–14 years is 4.1 per million per
year.
c The incidence of LCH in children in the UK and
Republic of Ireland in those aged under 1 year
age is 9.9 per million per year.
c This is the first national study of LCH to use a
prospective validated method of case
ascertainment such as the British Paediatric
Surveillance Unit.
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The list of over 1600 clinicians comprised relevant specialists
including dermatologists, endocrinologists, pathologists, radiol-
ogists, neurologists and orthopaedic surgeons. Additionally,
cases were cross-checked with the Children’s Cancer and
Leukaemia Group (CCLG) which registers in excess of 95% of
all UK and RoI childhood cancers.11
Reporting clinicians were sent a questionnaire to obtain
demographic and clinical details. A combination of date of birth,
hospital number, sex and the first part of the postcode was
collected in order to exclude duplicate reporting. A follow-up
form focusing on treatment and outcome was sent at 1 and
2 years after diagnosis, the information from which will be
reported later.
For completeness, deaths data were obtained from the UK
Office for National Statistics (ONS) and the Central Statistics
Office (CSO) in the RoI for those who died between 1996 and
2005 and had LCH mentioned anywhere on their death
certificate.
Cases were defined as children of any age resident in the UK
and RoI at diagnosis and newly diagnosed with either biopsy-
proven LCH or pituitary/hypothalamic abnormality, or lytic
bone lesion with the characteristics of LCH (but not biopsied
because of the risk of the procedure or because features
suggested spontaneous resolution). Cases were categorised as
having multisystem disease, with or without risk organ
involvement (RO+ or RO2), or single system disease, distin-
guishing between unifocal and multifocal bony involvement.
ONS annual mid-year population estimates for the study
period and census data for 2002 and 2006 for the RoI were used
in calculating age-standardised (to European Standard
Population) and age-specific incidence rates with corresponding
95% confidence intervals. Capture-recapture analysis was used
to estimate the number of cases missed by reporting sources.12
The mailing lists for the Newcastle University and BPSU
surveys were cross-checked and no clinician appeared on both
lists. CCLG cases may have been notified by clinicians already
surveyed by the BPSU or Newcastle University and were not
included in capture-recapture analysis. The use of two
independent sources, the BPSU and Newcastle University
surveys, allowed for an estimate of the overall population by
capture-recapture analysis. Potential seasonality of birth,
symptom onset and diagnosis were assessed using Edwards’
test with correction for differing month lengths.13 Statistical
analyses were performed using the statistical software package
Stata v 9 (StataCorp, College Station, TX). The study was given
appropriate ethics approval by UK and RoI ethics bodies.
RESULTS
Case ascertainment
On average, 92% of the report cards were returned to the BPSU
each month by paediatricians and an average of 53% of
clinicians responded to each mailing from the Newcastle
University survey.
Over 350 case notifications were received but, after removing
adult cases (over 16 years of age), cases diagnosed outside the
study period, misdiagnoses and duplicate reports, 94 cases were
confirmed. The reporting rates were CCLG 75/94 (80%), BPSU
69/94 (73%) and Newcastle University 58/94 (62%) (fig 1). No
additional cases were identified from the deaths data. Using
capture-recapture analysis the estimated total number of cases
was 102 (95% CI 89 to 126.2) rather than the 88 cases reported
by the BPSU and Newcastle sources. Case ascertainment for
each was estimated to be 69% and 58%, respectively, and overall
ascertainment by these two sources was 86%. However, a
further six cases were identified via the CCLG, all of whom
were treated by clinicians who had responded to the BPSU or
Newcastle surveys.
The surveys asked for ‘‘children of any age’’ to be reported,
whereas the CCLG registry includes those up to their 15th
birthday. However, at the upper age range there was a single 15-
year-old with unifocal bone disease reported to all three groups
and no 16-year-olds (fig 2).
Incidence
From our study population the age-standardised incidence
(ASR) of LCH in 0–14-year-olds is 4.12 per million per year
(95% CI 4.11 to 4.13). For those aged ,1 year the incidence is
9.9 per million per year (95% CI 5.5 to 16.3). ASRs and age-
specific incidence rates are shown in table 1. The population
studied covers 13 geographical health care regions. The regional
incidence varied from 2.6 to 6.0 per million per year, but analysis
of heterogeneity (using Cochran’s Q test) found no statistically
significant differences between health regions.
Reporting patterns
The pattern of reporting according to disease extent is shown in
table 2. The 10 cases identified uniquely by the Newcastle
University survey were all unifocal bone disease, eight of whom
were diagnosed and treated at a single national orthopaedic
centre. The two cases of multisystem, RO+ disease uniquely
Figure 1 Number of cases identified by source. BPSU, British
Paediatric Surveillance Unit; CCLG, Children’s Cancer and Leukaemia
Group; NCL, Newcastle University.
Figure 2 Number of cases by age at diagnosis.
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reported to the BPSU were diagnosed after death. Of the 25
cases not identified by the BPSU, 20 had unifocal bone disease,
but two cases of multisystem, RO2 disease were not reported.
Similarly, 16/19 of cases not reported to the CCLG were
unifocal bone disease. The CCLG were notified of all cases with
multifocal bone involvement and of multisystem disease, apart
from the two cases diagnosed at autopsy.
Diagnosis
Data were received on all of the confirmed 94 cases, although
questionnaires varied in their completeness. The number and
sex of cases, systems involved and age at diagnosis are shown in
table 3. There were 57 boys and 37 girls with an age range of
0.09–15.1 years. The M:F sex ratio was 1.5:1 increasing to 2.7:1
in children aged 10–14 years. Diagnostic biopsies were reported
in 78 cases. Typical radiological appearance was the basis of the
diagnosis in 11 bony lesions and two cases with isolated
diabetes insipidus. For one case of bone disease the basis of the
diagnosis was not stated and two cases were diagnosed at
autopsy.
Spectrum of disease
Overall, 69/94 (73%) cases had single system disease. Among
these were 53 cases of unifocal (15 skull vault; 8 pelvis; 7
vertebrae; 5 femur; 4 mandible; 3 humerus; 2 each orbit, facial,
scapula and clavicle; 1 each fibula, radius and rib) and 10 of
multifocal bone disease. The remainder comprised two cases
each with skin, pituitary and lymph node involvement. The
unifocal bone cases were diagnosed at a median age of 7.3 years
compared to 4.8 years for multifocal bone and 0.54 years for
skin disease.
Of the 25 multisystem cases, 18 were RO2 (14 bone, 8 skin, 5
diabetes insipidus and ear) and 7 RO+ (6 liver/spleen, 5 lung, 3
gut, 3 bone marrow). Whereas all RO+ cases had skin disease,
only one had bony involvement. The M:F ratio in this group
was 2.1:1 with the RO+ cases being diagnosed at the younger
median age of 0.7 years compared to 3.2 years in the RO2
patients. Three children died during the study period, all of
whom had multisystem, RO+ disease. However, LCH was not
the primary cause of death in one case.
Time to diagnosis
The time from first symptom to diagnosis is detailed in table 4.
There is wide variation with the longest median time to
diagnosis in patients with non-bony single system disease and
the shortest in patients with multisystem, RO+ disease. The
longest time to diagnosis, 170 weeks, was in a patient with a
single bony lesion.
Ethnicity and seasonality
Overall, 80% of children were of white Caucasian (95% CI 70 to
87%) and 13% (95% CI 7.6 to 22%) were of mixed or other
ethnicity. In 6% (95% CI 2.4 to 13%) of cases ethnicity was
unknown.
While there was no evidence of seasonality of birth (p = 0.93)
or of first symptom (p = 0.81), there was an association with
month of diagnosis (p = 0.04, amplitude 0.37); a higher number
of cases than expected (under an assumption of no seasonal
effect) were diagnosed from March to June.
Birth-associated factors
There were three sets of twins with one of each pair affected.
One was born prematurely and after many neonatal complica-
tions developed unifocal skull vault disease aged 1 year. The
two other cases (2%: 95% CI 0.2 to 7%) were reported to have
been conceived by IVF. One developed unifocal vertebral bone
disease at age 11 years and the other had congenital self-healing
histiocytosis (Hashimoto-Pritzker disease). There were three
other congenital cases; one boy with proptosis and two boys
with multisystem disease, one of whom was RO+ and died.
Birth weights and gestational age were similar to national
averages, the medians being 3.3 kg and 39 weeks, respectively.
Associated diagnoses
Two children had medulloblastoma. In one case the tumour
preceded the diagnosis of single system, unifocal bone disease.
The second was diagnosed 6 months after single system,
unifocal bone disease which had not required treatment. One
child had partial trisomy 3. Other conditions preceding
diagnosis of LCH included seizure disorder and developmental
Table 1 Estimation of incidence rates
Age (years) ASR
IRs ,1 1–4 5–9 10–14 0–14
Boys 10.3 5.7 5.0 2.6 4.7 4.8
Girls 9.5 3.8 3.9 1.0 3.2 3.4
Both 9.9 4.8 4.5 1.8 3.9 4.1
Sex ratio 1.1 1.5 1.3 2.7 1.5
ASR, age-standardised incidence; IR, incidence rates.
Table 2 Pattern of case reporting showing types of cases uniquely identified and not identified by each
source
Source Total cases
Single system disease Multisystem disease
Bony
Other RO+ RO2Unifocal Multifocal
Total 94 53 10 6 7 18
Uniquely identified by
BPSU 6 3 1 2
Newcastle University 10 10
CCLG 6 4 1 1
Not identified by
BPSU 25 20 2 1 2
Newcastle University 36 19 3 3 5 6
CCLG 19 16 1 2
BPSU, British Paediatric Surveillance Unit; CCLG, Children’s Cancer and Leukaemia Group; RO+, with risk organ involvement; RO2,
without risk organ involvement.
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delay in one child and pneumothorax and necrotising enter-
ocolitis in the preterm twin.
One of each of the following conditions were reported in the
maternal histories of pregnancy: Darier’s disease (affected child
had multisystem, RO+ disease, diagnosed at autopsy), hypothyr-
oidism, epilepsy, melanoma, thalassaemia, asthma/psoriasis,
diabetes/epilepsy and cholestasis.
DISCUSSION
Our age-specific incidence rate for 0–15-year-olds was 3.7 per
million per year (95% CI 3.0 to 4.6) with over 86% of cases
estimated to have been ascertained. In comparison with other
studies, our ASR of 4.1 per million per year in children aged 0–
14 years is higher than the 2.5 per million per year (42 cases
from 1968–1995) and the 2.6 per million per year (101 cases
from 1954–1998) reported by children’s cancer registries in the
northeast and northwest of England.7 9 Interestingly, our
incidence rates for these regions were 3.1 and 4.4 per million
per year, respectively, which taken with our overall rate may
suggest a degree of under-reporting or under-diagnosis in these
previous studies. An increase in incidence of LCH may also be a
possibility for the variation, although Alston et al found no
evidence of this in their study of cases diagnosed over a 40-year
period.7
Other national studies have reported comparable incidence
rates (2.2–6.0 per million per year).1 3 4 8 The different rates may
simply reflect the different methods of ascertainment, especially
as discussed below for unifocal bone disease, or may reflect the
small number of cases. However, in all these studies where data
are available, the incidence rate drops markedly beyond the age
of 10 years, suggesting the possibility that small variations
beyond this age may be contributing to the reported differences.
Our findings are comparable with other national studies in
that the peak incidence was in children aged 0–4 years, there
was a predominance of boys and the majority of cases were
bone disease.1 2 6
LCH cases are not included in national cancer statistics in the
UK and cases treated without chemotherapy may not be
registered with the CCLG. The use of the BPSU survey system
was therefore attractive. However, LCH is diagnosed by a wide
spectrum of clinicians and it has always been appreciated that
uncomplicated bone disease (eosinophilic granuloma) in older
children may be treated without paediatric input. For these
reasons our study was designed to use three complementary
methods of ascertainment. In general the pattern of reporting
confirmed the limitations of each method. Significantly, only
three cases of non-bony single system, multifocal bone or
multisystem disease were uniquely identified, suggesting that
these cases have been appropriately collected. The majority of
cases not reported by the CCLG or BPSU were of unifocal bone
disease, the cases missed by the CCLG requiring little or no
treatment. Nineteen cases were not identified by the Newcastle
University survey, which extended outside general paediatrics.
However, all ten cases uniquely reported, were, as expected,
unifocal bone, which may indicate under-reporting in this area.
During the study period the Histiocyte Society trial LCH III
commenced with randomised chemotherapy protocols for
patients with multisystem RO+ or RO2 disease. The trial,
which additionally recommended chemotherapy for, and
collected data on, patients with multifocal or special site
unifocal bony disease, undoubtedly contributed to the apparent
100% registration of these patients with the CCLG.
As expected for any rare disease, the time from first symptom
to diagnosis was very varied, ranging from a few days to over
3 years for one patient with unifocal bone disease. The shortest
median time of 9.2 weeks (range 3.1–26.7) was for patients with
multisystem RO+ disease. The longest median interval,
29 weeks (range 6.7–37), was reported for the six children with
‘‘other’’ disease (two each of single system lymph node, skin
and diabetes insipidus).
LCH has been predominantly reported in white children,
although this may be due to a reporting bias. The proportion of
non-white cases in our study (13%) was not significantly
different from that among the total UK population (7.9%)
reported in the 2001 census, and was the same as that reported
in a UK hospital series between 1980 and 1987 (8/58 cases).14 15
Two cases were born after IVF treatment which is similar to
the proportion of artificial reproductive technology (ART)
births in the UK population (1.3%), although it is not known
if any other cases were conceived by IVF or other forms of
ART.16
An association was found with month of diagnosis, with
more cases being reported in the spring (March–June), although
Table 3 Cases of Langerhans cell histiocytosis by type of disease, sex and age at diagnosis
LCH system Number
Sex
Median age
at diagnosis
Age range
(years)Male Female
Single system 69 40 29 6.7 0.12–15.1
Bone 63 36 27 6.7 0.38–15.1
Unifocal 53 31 22 7.3 0.38–15.1
Multifocal 10 5 5 4.8 1.58–13.63
Skin 2 1 1 0.54 0.12–0.96
Other 4 3 1 9.8 8.8–10.0
Multisystem 25 17 8 1.2 0.09–14.8
RO+ 7 5 2 0.7 0.09–0.9
RO2 18 12 6 3.2 0.32–14.8
LCH, Langerhans cell histiocytosis; RO+, with risk organ involvement; RO2, without risk organ involvement.
Table 4 Number of weeks from first symptom to
diagnosis
LCH system Median Range
Single system 10 0.5–170
Bone 10 0.5–170
Unifocal 10 0.5–170
Multifocal 13 0.5–65
Other 29 6.7–37
Multisystem 16 2.5–149
RO+ 9 3.1–26.7
RO2 17 2.5–149
LCH, Langerhans cell histiocytosis; RO+, with risk organ involvement;
RO2, without risk organ involvement.
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it is recognised that Edwards’ test is unreliable with small
samples of data. However, no evidence of seasonality by month
of birth, month of first symptom or month of diagnosis was
found in a study in the northwest of England over four decades.7
In the study in Stockholm county, 75% of cases were diagnosed
during the autumn and winter months.6 Other studies have
reported a higher incidence in summer months in wet regions or
during periods of high rainfall.5 17 Variation in seasonal infection
rates and school holidays may contribute to this apparent
association.
In two US studies of risk factors, LCH was associated with
maternal urinary tract infections, feeding problems and medica-
tion in infancy, a family history of thyroid disease and infections
in the postnatal period.18 19 Our questionnaire included questions
on family history, pregnancy and neonatal history, but only one
mother with a thyroid condition and only single cases of
infections or other conditions were reported. Further large studies
are needed to look for possible aetiological factors.
This is the first national study of LCH to use a well-
established active surveillance method with additional sources
of case ascertainment. The study had the advantage of using an
established (and enhanced) large network inclusive of multi-
specialty clinicians rather than ascertainment via a cancer
registry. However, with only 2 years of case ascertainment the
number of cases is too low to form different groups within the
study.
Our incidence rate is likely to be an underestimate given our
estimate of the total number of cases by capture-recapture
analysis. Each method may have missed recognised cases and
mild cases that may never have been diagnosed. Our findings
suggest that cancer registries and specialty groups alone may be
insufficient to ascertain all cases of LCH and that future studies
should cast a wide net. However, by using several sources to
maximise ascertainment, sufficient data have been collected to
assess presentation, management and outcome which we aim to
present in a future publication.
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